{"id":5319,"date":"2020-06-01T11:54:43","date_gmt":"2020-06-01T10:54:43","guid":{"rendered":"https:\/\/www.innovationnewsnetwork.com\/?p=5319"},"modified":"2020-06-01T11:54:43","modified_gmt":"2020-06-01T10:54:43","slug":"developing-passive-immunotherapy-methods-for-covid-19","status":"publish","type":"post","link":"https:\/\/www.innovationnewsnetwork.com\/developing-passive-immunotherapy-methods-for-covid-19\/5319\/","title":{"rendered":"Developing passive immunotherapy methods for COVID-19"},"content":{"rendered":"
The new Horizon 2020 project, Antibody Therapy Against Coronavirus<\/a> (ATAC), aims to develop passive immunotherapy methods against COVID-19<\/a>. The research team are currently using human antibodies from recovered COVID-19 patients to test different passive immunotherapy methods.<\/p>\n According to a recently published ATAC fact sheet: \u2018Antibodies will be characterised by rapid experimental and computational work, optimised, produced and tested in consultation with EMA to ensure prompt embedding of regulatory aspects.\u2019<\/p>\n The team from the ATAC project consortium have tested blood plasma transfusions<\/a> in patients and discovered that this method can provide promising results. Unfortunately, a single plasma donation can only treat one person.<\/p>\n \u201cThere is quite a difference between patients in terms of how many antibodies they have. You can go from almost nothing to quite impressive immune responses,\u201d said Dr Rino Rappuoli, an internationally recognised vaccinologist working on the ATAC project.<\/p>\nSuccessful methods using blood plasma<\/h3>\n